NYSE:CVS
CVS HEALTH Corp
A diversified healthcare giant combining retail pharmacy, insurance services, and wholesale distribution with a strong focus on value-based care initiatives.
Key Metrics
Investment Thesis
Bull Case
CVS offers defensive exposure to the essential healthcare sector with a dominant market position that provides stable, recurring revenue streams from insurance premiums and prescription fills; the company's robust cash generation allows for consistent dividend payments of $3.40B annually without relying on share repurchases; strategic investments in digital health and value-based care models may unlock future margin expansion as the industry shifts away from volume-driven pricing.
Bear Case
The sharp decline in net income to $1.73B suggests underlying profitability challenges that may persist if wholesale volumes contract or regulatory headwinds intensify; high levels of goodwill at $85.48B and accumulated other comprehensive losses indicate potential future write-downs or accounting adjustments that could surprise investors; the heavy reliance on third-party pharmaceutical rebates means earnings are highly sensitive to negotiations with drug manufacturers which can be unpredictable.
About CVS HEALTH Corp
CVS Health Corp operates as a leading healthcare services provider offering pharmacy retail, healthcare services, and wholesale distribution across the United States. The company serves millions of patients through its extensive network of MinuteClinics, pharmacies, and insurance plans while managing a massive wholesale business. Key revenue streams include prescription drug sales, health insurance premiums, and specialized pharmaceutical distribution.
Analysis
Management Discussion
While revenue grew to $402.07B in 2025, net income dropped significantly to $1.73B from $4.59B the prior year, indicating substantial pressure on profitability despite top-line expansion. Operating expenses surged to $176.24B against $221.17B in cost of revenue, compressing gross profit margins and reducing the operating profit ratio. The company generated strong cash flow from operations of $10.64B but utilized significant capital for investing activities (-$5.87B) and financing outflows (-$4.94B), resulting in a slight net decrease in cash.
Industry Overview
The US healthcare sector is undergoing a structural transformation driven by aging demographics, rising chronic disease prevalence, and increasing government pressure to lower prescription drug costs. Companies must adapt by integrating insurance and retail services to capture value while navigating complex regulatory environments that limit traditional margin models.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $322.47B | $357.78B | $372.81B | $402.07B |
| Cost of Revenue | $196.89B | $217.10B | $206.29B | $221.17B |
| Gross Profit | $125.58B | $140.68B | $166.52B | $180.90B |
| Operating Expenses | $117.83B | $126.94B | $158.01B | $176.24B |
| Operating Income | $7.75B | $13.74B | $8.52B | $4.66B |
| Stock-Based Comp | $447.0M | $588.0M | $540.0M | $535.0M |
| D&A | $4.25B | $4.37B | $4.60B | $4.61B |
| Depreciation | $2.40B | $2.50B | $2.60B | $2.60B |
| Amortization | $1.81B | $1.91B | $2.02B | $1.98B |
| Non-Operating Income | $-2.12B | $-2.57B | $-2.37B | $-2.52B |
| Interest Expense | $2.29B | $2.66B | — | — |
| Pre-Tax Income | $5.63B | $11.17B | $6.15B | $2.14B |
| Income Tax | $1.46B | $2.81B | $1.56B | $408.0M |
| Continuing Ops | $4.17B | $8.37B | $4.59B | $1.73B |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $4.17B | $8.37B | $4.59B | $1.73B |
| Minority Interest | $16.0M | $24.0M | $-28.0M | $-40.0M |
| Net to Common | $4.15B | $8.34B | $4.61B | $1.77B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $65.68B | $67.86B | $68.64B | $74.71B |
| Cash & Equivalents | $12.95B | $8.20B | $8.59B | $8.45B |
| Marketable Securities | $2.78B | $3.26B | $2.41B | $2.15B |
| Accounts Receivable | $27.28B | $35.23B | $36.47B | $39.78B |
| Inventory | $19.09B | $18.02B | $18.11B | $19.25B |
| Other Current Assets | $3.59B | $3.15B | $3.08B | $5.09B |
| Long-Term Assets | $162.59B | $181.87B | $184.57B | $178.82B |
| PP&E (Net) | $12.87B | — | — | — |
| Intangibles | $24.75B | $29.23B | $27.32B | $25.51B |
| Goodwill | $78.15B | $91.27B | $91.27B | $85.48B |
| Operating Leases | $17.87B | $17.25B | $15.94B | $14.97B |
| LT Investments | $21.10B | $23.02B | $28.93B | $32.67B |
| Other LT Assets | $7.85B | $21.09B | $21.10B | $20.20B |
| Total Assets | $228.28B | $249.73B | $253.22B | $253.54B |
| Current Liabilities | $69.74B | $79.19B | $84.61B | $88.69B |
| Current Leases | $1.68B | $1.74B | $1.75B | $1.74B |
| Deferred Revenue | $71.0M | $149.0M | $144.0M | $62.0M |
| Other Current Liab | $49.24B | $55.11B | $61.90B | $64.51B |
| Long-Term Liabilities | $87.22B | $93.90B | $92.88B | $89.46B |
| LT Operating Leases | $16.80B | $16.03B | $14.90B | $13.64B |
| Other LT Liab | $70.42B | $77.67B | $75.86B | $75.82B |
| Total Liabilities | $156.96B | $173.09B | $177.49B | $178.16B |
| Shareholders' Equity | $71.31B | $76.64B | $75.73B | $75.38B |
| Paid-In Capital | $48.19B | $48.99B | $49.66B | $50.40B |
| Retained Earnings | $56.15B | $61.60B | $62.84B | $61.20B |
| AOCI | $-1.47B | $-297.0M | $-120.0M | $406.0M |
| Treasury Stock | $31.86B | — | — | — |
| Total L&E | $228.28B | $249.73B | $253.22B | $253.54B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $4.17B | $8.37B | $4.59B | $1.73B |
| Non-Cash Adjustments | $-4.93B | $-6.03B | $1.53B | $-4.33B |
| Working Capital Changes | $16.95B | $11.09B | $2.99B | $13.24B |
| Cash from Operations | $16.18B | $13.43B | $9.11B | $10.64B |
| Capital Expenditures | $2.73B | $3.03B | $2.78B | $2.83B |
| Cash from Investing | $-5.05B | $-20.89B | $-7.61B | $-5.87B |
| Debt Issuances | $0 | $10.90B | $7.91B | $3.97B |
| Debt Repayments | $4.21B | $3.17B | $4.77B | $3.63B |
| Share Buybacks | $3.50B | $2.01B | $3.02B | $0 |
| Dividends Paid | $2.91B | $3.13B | $3.37B | $3.40B |
| Cash from Financing | $-10.52B | $2.68B | $-1.14B | $-4.94B |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $614.0M | $-4.78B | $359.0M | $-172.0M |
| Beginning Cash | $12.69B | $13.30B | $8.53B | $8.88B |
| Ending Cash | $13.30B | $8.53B | $8.88B | $8.71B |
Frequently Asked Questions
How does CVS HEALTH Corp make money?
The company's revenue is driven by three primary pillars: Pharmacy Retail (including MinuteClinics and insurance), Health Care Services (primarily Aetna insurance products), and Specialty Wholesale Distribution which handles high-cost biologic drugs for other pharmacy chains and distributors.
What are the main risks for CVS?
Regulatory changes regarding drug pricing transparency and reimbursement rates could materially impact margins; exposure to volatile pharmaceutical wholesale volumes and supply chain disruptions affecting drug availability; potential erosion of pharmacy foot traffic due to the rapid growth of direct-to-consumer telehealth and mail-order options; and sensitivity to interest rate fluctuations given their significant debt load and lease liabilities.
What is CVS's competitive advantage?
CVS possesses the most extensive physical network of pharmacies and clinics in the US, providing unmatched patient accessibility; its integrated ecosystem allows it to capture value across the entire care continuum from retail sales to insurance administration; and its scale enables significant bargaining power with pharmaceutical manufacturers for rebates and pricing.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.